KalVista Pharmaceuticals (NASDAQ:KALV) Insider Nicole Sweeny Sells 1,862 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,862 shares of the firm’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $20.22, for a total value of $37,649.64. Following the sale, the insider directly owned 51,391 shares of the company’s stock, valued at $1,039,126.02. This represents a 3.50% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Monday, February 23rd, Nicole Sweeny sold 3,975 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $15.57, for a total value of $61,890.75.

KalVista Pharmaceuticals Trading Up 1.9%

Shares of KalVista Pharmaceuticals stock opened at $20.87 on Tuesday. The business has a fifty day simple moving average of $17.50 and a two-hundred day simple moving average of $15.23. KalVista Pharmaceuticals, Inc. has a 1 year low of $9.83 and a 1 year high of $21.31. The company has a market capitalization of $1.07 billion, a price-to-earnings ratio of -5.28 and a beta of -0.40. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

Analyst Ratings Changes

KALV has been the topic of several research analyst reports. Wall Street Zen cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. HC Wainwright upped their price objective on KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a report on Friday, January 9th. Citizens Jmp decreased their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Thursday, March 26th. Finally, Needham & Company LLC upped their price objective on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a “buy” rating in a report on Wednesday, March 25th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $32.60.

KalVista Pharmaceuticals News Roundup

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Several sell‑side firms have raised price targets and reiterated buy ratings (HC Wainwright, Stifel, Needham), and recent filings show large institutional stakes being established or increased — a combination that supports upward momentum and a consensus target materially above the current price. MarketBeat coverage
• Neutral Sentiment: Company fundamentals and technicals offer context: market cap ≈ $1.07B, very strong liquidity (current and quick ratios ≈7.2) and the 50‑day / 200‑day moving averages ($17.50 / $15.23) sit below the current trade — supportive background but not an immediate catalyst for price moves.
• Negative Sentiment: Multiple insiders sold shares on April 17 (CEO Benjamin Palleiko sold 9,550 shares at ~$20.22; CFO Brian Piekos and other insiders also sold smaller blocks). Filings say sales were to cover tax withholding on vested awards, but concentrated insider selling can still create short‑term downward pressure or investor concern. InsiderTrades alert

Institutional Trading of KalVista Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Tudor Investment Corp ET AL bought a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $24,360,000. Emerald Advisers LLC boosted its holdings in KalVista Pharmaceuticals by 30.2% in the 3rd quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock valued at $16,458,000 after purchasing an additional 313,205 shares during the period. Jefferies Financial Group Inc. bought a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $3,494,000. Blue Owl Capital Holdings LP bought a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $1,522,000. Finally, Emerald Mutual Fund Advisers Trust raised its holdings in KalVista Pharmaceuticals by 19.4% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 917,975 shares of the specialty pharmaceutical company’s stock valued at $11,181,000 after acquiring an additional 149,003 shares in the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.